Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease.  License and collaboration agreement strengthen Boehringer’s inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset. Boehringer receives global rights to the asset, excluding greater China; Simcere is eligible to receive payments of up to EUR 1,058 million   Ingelheim, Germany, and Shanghai, China, 26, January 2026 – Boehringer Ingelheim a ...